Home > Keywords > Thématique > Partenariat

Partenariat

Articles

  • Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
    3 February, by Emmanuelle BETTENDORF

    We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.
    “We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with (…)

  • Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
    30 January 2024, by Emmanuelle BETTENDORF

    Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that (…)

  • RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC
    19 September 2025, by Emmanuelle BETTENDORF

    Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).
    “The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.
    “We are looking forward (…)

  • Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
    6 March 2019, by Jonathan NOWAK

    Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.
    This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and (…)

  • Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
    17 November 2020, by Elodie DORMES

    Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
    With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

  • Vect-Horus announces agreement with Johnson&Johnson Innovation
    18 January 2019, by Jonathan NOWAK

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
    11 July 2025, by Emmanuelle BETTENDORF

    We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!
    The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.
    The combination of these two technologies will expand Secarna’s targeted (…)

  • Relocation of the company to support its development
    1 October 2019, by Elodie DORMES

    Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.

  • Vect-Horus enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.
    26 March 2019, by Jonathan NOWAK

    Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases

  • Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
    28 January 2019, by Jonathan NOWAK

    The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)